O	0	8	Reducing
O	9	19	persistent
B-condition	20	33	postoperative
I-condition	34	38	pain
O	39	42	and
O	43	53	disability
O	54	55	1
O	56	60	year
O	61	66	after
O	67	73	breast
O	74	80	cancer
O	81	88	surgery
O	88	89	:
O	90	91	a
O	92	102	randomized
O	102	103	,
O	104	114	controlled
O	115	120	trial
O	121	130	comparing
B-intervention	131	139	thoracic
I-intervention	140	153	paravertebral
I-intervention	154	159	block
O	160	162	to
B-control	163	168	local
I-control	169	179	anesthetic
I-control	180	192	infiltration
O	192	193	.

O	194	197	The
O	198	207	objective
O	208	210	of
O	211	215	this
O	216	221	study
O	222	225	was
O	226	228	to
O	229	236	compare
O	237	240	the
O	241	247	effect
O	248	250	of
O	251	259	thoracic
O	260	273	paravertebral
O	274	279	block
O	280	281	(
O	281	285	TPVB
O	285	286	)
O	287	290	and
O	291	296	local
O	297	307	anesthetic
O	308	309	(
O	309	311	LA
O	311	312	)
O	313	315	on
B-outcome-Measure	316	326	persistent
I-outcome-Measure	327	340	postoperative
I-outcome-Measure	341	345	pain
I-outcome-Measure	346	347	(
I-outcome-Measure	347	350	PPP
I-outcome-Measure	350	351	)
O	352	353	1
O	354	358	year
O	359	368	following
O	369	375	breast
O	376	382	cancer
O	383	390	surgery
O	390	391	.

O	392	401	Secondary
O	402	412	objectives
O	413	417	were
O	418	420	to
O	421	428	compare
O	429	432	the
O	433	439	effect
O	440	442	on
B-outcome-Measure	443	446	arm
I-outcome-Measure	447	456	morbidity
O	457	460	and
B-outcome-Measure	461	468	quality
I-outcome-Measure	469	471	of
I-outcome-Measure	472	476	life
O	476	477	.

B-eligibility	478	483	Women
I-eligibility	484	493	scheduled
I-eligibility	494	497	for
I-eligibility	498	506	elective
I-eligibility	507	513	breast
I-eligibility	514	520	cancer
I-eligibility	521	528	surgery
I-eligibility	529	533	were
I-eligibility	534	542	randomly
O	543	551	assigned
O	552	554	to
O	555	561	either
O	562	566	TPVB
O	567	569	or
O	570	572	LA
O	573	581	followed
O	582	584	by
O	585	592	general
O	593	603	anesthesia
O	603	604	.

O	605	607	An
O	608	611	NRS
O	612	617	value
O	618	620	of
O	621	622	>
O	622	623	3
O	624	626	at
O	627	631	rest
O	632	634	or
O	635	639	with
O	640	648	movement
O	649	650	1
O	651	655	year
O	656	665	following
O	666	673	surgery
O	674	681	defined
O	682	685	PPP
O	685	686	.

O	687	694	Blinded
O	695	702	interim
O	703	711	analysis
O	712	721	suggested
O	722	727	rates
O	728	730	of
O	731	734	PPP
O	735	739	much
O	740	745	lower
O	746	750	than
O	751	762	anticipated
O	762	763	,
O	764	770	making
O	771	780	detection
O	781	783	of
O	784	787	the
O	788	797	specified
O	798	800	20
O	801	802	%
O	803	811	absolute
O	812	821	reduction
O	822	824	in
O	825	828	the
O	829	836	primary
O	837	844	outcome
O	845	855	impossible
O	855	856	.

O	857	868	Recruitment
O	869	872	was
O	873	880	stopped
O	880	881	,
O	882	885	and
O	886	889	all
O	890	898	enrolled
O	899	907	patients
O	908	912	were
O	913	921	followed
O	922	924	to
O	925	926	1
O	927	931	year
O	931	932	.

O	933	934	A
O	935	940	total
O	941	943	of
B-total-participants	944	947	145
O	948	960	participants
O	961	965	were
O	966	975	recruited
O	975	976	;
B-intervention-participants	977	979	65
O	980	984	were
O	985	995	randomized
O	996	998	to
O	999	1003	TPVB
O	1004	1007	and
B-control-participants	1008	1010	64
O	1011	1013	to
O	1014	1016	LA
O	1016	1017	.

O	1018	1024	Groups
O	1025	1029	were
O	1030	1037	similar
O	1038	1042	with
O	1043	1050	respect
O	1051	1053	to
O	1054	1065	demographic
O	1066	1069	and
O	1070	1079	treatment
O	1080	1095	characteristics
O	1095	1096	.

O	1097	1101	Only
O	1102	1103	9
O	1104	1112	patients
O	1113	1114	(
O	1114	1115	8
O	1116	1117	%
O	1117	1118	;
O	1119	1121	95
O	1122	1123	%
O	1124	1126	CI
O	1127	1128	4
O	1128	1129	-
O	1129	1131	14
O	1132	1133	%
O	1133	1134	)
B-outcome	1135	1138	met
I-outcome	1139	1147	criteria
I-outcome	1148	1151	for
I-outcome	1152	1155	PPP
O	1156	1157	1
O	1158	1162	year
O	1163	1172	following
O	1173	1180	surgery
O	1180	1181	;
B-iv-bin-abs	1182	1183	5
O	1184	1188	were
O	1189	1191	in
O	1192	1195	the
O	1196	1200	TPVB
O	1201	1204	and
B-cv-bin-abs	1205	1206	4
O	1207	1209	in
O	1210	1213	the
O	1214	1216	LA
O	1217	1222	group
O	1222	1223	.

B-outcome	1224	1229	Brief
I-outcome	1230	1234	Pain
I-outcome	1235	1244	Inventory
I-outcome	1245	1253	severity
I-outcome	1254	1257	and
I-outcome	1258	1270	interference
I-outcome	1271	1277	scores
O	1278	1282	were
O	1283	1286	low
O	1287	1289	in
O	1290	1294	both
O	1295	1301	groups
O	1301	1302	.

B-outcome	1303	1306	Arm
I-outcome	1307	1316	morbidity
I-outcome	1317	1320	and
I-outcome	1321	1328	quality
I-outcome	1329	1331	of
I-outcome	1332	1336	life
O	1337	1341	were
O	1342	1349	similar
O	1350	1352	in
O	1353	1357	both
O	1358	1364	groups
O	1364	1365	.

O	1366	1369	The
O	1370	1371	9
O	1372	1380	patients
O	1381	1385	with
O	1386	1389	PPP
O	1390	1398	reported
B-outcome	1399	1407	shoulder
I-outcome	1407	1408	-
I-outcome	1408	1411	arm
I-outcome	1412	1421	morbidity
O	1422	1425	and
O	1426	1433	reduced
B-outcome	1434	1441	quality
I-outcome	1442	1444	of
I-outcome	1445	1449	life
O	1449	1450	.

O	1451	1455	This
O	1456	1461	study
O	1462	1469	reports
O	1470	1471	a
O	1472	1475	low
O	1476	1485	incidence
O	1486	1488	of
O	1489	1496	chronic
O	1497	1501	pain
O	1502	1503	1
O	1504	1508	year
O	1509	1518	following
O	1519	1524	major
O	1525	1531	breast
O	1532	1538	cancer
O	1539	1546	surgery
O	1546	1547	.

O	1548	1556	Although
O	1557	1560	PPP
O	1561	1564	was
O	1565	1573	uncommon
O	1574	1576	at
O	1577	1578	1
O	1579	1583	year
O	1583	1584	,
O	1585	1587	it
O	1588	1591	had
O	1592	1593	a
O	1594	1599	large
O	1600	1606	impact
O	1607	1609	on
O	1610	1613	the
O	1614	1622	affected
O	1623	1631	patients
O	1631	1632	'
O	1633	1636	arm
O	1637	1646	morbidity
O	1647	1650	and
O	1651	1658	quality
O	1659	1661	of
O	1662	1666	life
O	1666	1667	.
